Cue Biopharma (NASDAQ:CUE) Downgraded to Buy Rating by Wall Street Zen

Key Points

• Cue Biopharma was downgraded by Wall Street Zen from "strong-buy" to "buy," while Weiss Ratings reaffirmed a "sell (e+)" and the stock's consensus rating on MarketBeat is "Sell".
• Shares trade around $30.42 with a 52‑week range of $4.97–$38.00 and a market capitalization of about $98.6 million; the company shows a negative P/E (-3.17) and a beta of 2.37.
• Several institutional investors have recently increased positions in CUE, and institutions now own roughly 35.04% of the stock.

Cue Biopharma (NASDAQ:CUE - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research report issued on Sunday.

Separately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Cue Biopharma in a research report on Friday, March 27th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Cue Biopharma currently has a consensus rating of "Sell".

Cue Biopharma Stock Performance

Shares of Cue Biopharma stock opened at $30.42 on Friday. Cue Biopharma has a 52-week low of $4.97 and a 52-week high of $38.00. The company's 50 day moving average price is $267.38 and its 200-day moving average price is $377.38. The stock has a market capitalization of $98.56 million, a price-to-earnings ratio of -3.17 and a beta of 2.37.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of CUE. Northwestern Mutual Wealth Management Co. boosted its position in shares of Cue Biopharma by 730.0% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company's stock valued at $57,000 after acquiring an additional 73,000 shares during the last quarter. Squarepoint Ops LLC bought a new position in shares of Cue Biopharma during the 3rd quarter valued at approximately $62,000. Stifel Financial Corp boosted its position in shares of Cue Biopharma by 25.4% during the 4th quarter. Stifel Financial Corp now owns 246,556 shares of the company's stock valued at $75,000 after acquiring an additional 50,000 shares during the last quarter. Texas Capital Bank Wealth Management Services Inc lifted its position in Cue Biopharma by 1,231.2% in the fourth quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company's stock worth $135,000 after buying an additional 407,568 shares during the last quarter. Finally, Boothbay Fund Management LLC lifted its position in Cue Biopharma by 15.3% in the fourth quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company's stock worth $215,000 after buying an additional 93,333 shares during the last quarter. 35.04% of the stock is currently owned by institutional investors.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company's proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.